Eli Lilly company headlines, earnings, strategy, leadership, and market-moving business updates.
Market data may be delayed. For informational purposes only. Not investment advice.
The small-cap discovery technology company OmniAb said it has entered a global collaboration and licensing arrangement tied to an ion channel therapeutic program with Eli Lilly (LLY). Details on economics and timelines were not provided in the announcement cited by the market news post.
THE APEX TIMES
THE APEX TIMES
A recent market-news post argues that GLP-1 growth is driving demand beyond the usual duopoly of Eli Lilly and Novo Nordisk, spotlighting two other companies as potential beneficiaries.
THE APEX TIMES
The company says multiple lawsuits target U.S. entities accused of marketing versions of retatrutide that are not authorized by Lilly.
THE APEX TIMES
The U.K. health regulator has approved Eli Lilly’s latest oral weight-loss treatment, marking what the company’s backers are calling Europe’s first approval of its kind and adding momentum to the company’s push in obesity care.
THE APEX TIMES
A recent market note says Eli Lilly’s stock has gained on earnings momentum, and the chart is approaching levels some traders watch. The post also warns the setup is not a perfect fit.
THE APEX TIMES
Eli Lilly’s second-quarter update drew a cautiously constructive reaction in markets, even as the company fell short of Wall Street’s revenue expectations. On the earnings call, management pointed to momentum in its cardiometabolic franchise, prompting a wave of questions on sustainability, capacity, and pipeline progress.
THE APEX TIMES
A new market argument says affordability pressures around GLP-1 therapies could ultimately expand Eli Lilly’s addressable market rather than cap it.
THE APEX TIMES
A reported marketing dispute between Novo Nordisk and Eli Lilly is drawing attention to how brand positioning, not just drug performance, may shape outcomes in the obesity market.
THE APEX TIMES
A regulator approval announced Aug. 10 gives Eli Lilly’s weight-loss drug a new form factor: a daily pill designed to reach patients who may prefer tablets over injections.
